- Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in hospitalized patients with COVID-19 associated pneumonia and acute respiratory distress syndrome (ARDS).
- This analysis updates the preliminary topline data reported in January.
- The updated data demonstrated a higher proportion of patients alive and free of respiratory failure over the 28-day study period (primary endpoint) compared to placebo.
- At both the 28-day and the 60-day final timepoints, an approximately 50% trend in mortality reduction (22.5% vs. 10.8%) was observed.
- Efficacy was highest in patients over the age of 60.
- CERC-002 showed statistically significant efficacy on top of corticosteroids and standard of care treatments in COVID-19 ARDS.
- The treatment was well-tolerated, with no drug-related serious adverse effects were reported.
- The Company plans to meet with FDA to discuss the potential path to Emergency Use Authorization and approval.
- Price Action: CERC shares were trading 13.9% higher at $4.25 in the premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in